COVID-19 Vaccine

Boosters are approved and recommended for all patients 12 and older 5 months after their primary Pfizer or Moderna vaccine series or 2 months after an initial J&J dose. At this time, only Pfizer boosters are approved for those 5 to 17 years-old.

Location: 3060 Salt Creek Lane, Arlington Heights.

• (Pfizer) Tuesdays, 9 a.m. – 6 p.m.
• (Moderna) Wednesdays, 9 a.m. to 6 p.m.

We are vaccinating kids aged 5-11 years-old with Pfizer (the only approved vaccine for this age group). A parent or legal guardian must accompany the child to provide consent to care.

Location: 3060 Salt Creek Lane, Arlington Heights

• Tuesdays only: 3:30 p.m. to 6 p.m.

NCH is vaccinating all patients 12 and older. A parent or legal guardian must accompany the child to provide consent to care.

Locations: Immediate Care Centers in Buffalo Grove, Schaumburg, Kildeer, Mount Prospect and on the campus of Harper College in Palatine.

Updated CDC guidance recommends an additional primary dose (3rd dose) to immunocompromised children aged 5-11 years-old 28 days after their primary vaccination series. It has approved a booster (4th dose) for all patients 12 and up 5 months after their 3rd dose.

Patients who are immunocompromised should call the NCH Vaccine Hotline at 847-618-0242 to schedule an appointment.

Immunocompromised patients include those who are:

• In active treatment for solid tumor and hematologic malignancies
• In receipt of solid-organ transplant and taking immunosuppressive therapy
• In receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
• Have moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced or untreated HIV infection
• In active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers and other biologic agents that are immunosuppressive or immunomodulatory.